Herein, we examine the transcriptomic expression level of TIM‐3 in 514 patients with diverse cancers and demonstrate that TIM‐3 expression levels are variable across tumors, but are elevated more frequently in pancreatic adenocarcinomas as compared to other cancers, suggesting that TIM‐3 therapeutic targeting may be warranted in pancreatic malignancies. The gene discussed is HAVCR2; the disease is pancreatic adenocarcinoma.